Foreign aid cuts could lead to millions more dying from superbug infections by 2050, study warns
Without collective global action, growing cases of infections caused by such antimicrobial-resistant (AMR) microbes could cost the global economy nearly $2trillion, the UK government-funded research says.
The research forecasts the future impact of AMR on global economies under different scenarios of interventions across regions, income groups, and countries.
Bacteria have been evolving resistance to the antibiotics used by doctors to kill them in recent years, causing even what used to be the simplest-to-treat infections to become potentially life-threatening.
With scientists locked in a race to create and improve access to a 'new generation' of drugs capable of defeating even the most resistant of such superbugs, global research funding cuts risk stalling progress.
If the superbug spread continued at the same trend as seen since 1990 in a 'business-as-usual' scenario, it could lead to nearly 39 million deaths between 2025 and 2050, a growing body of studies suggests.
However, if there is improved access to antibiotics against such bacterial infections, it could avert 90 million deaths over this period, the latest report estimates.
Better access to antibiotics could lead to a $19bn annual reduction in healthcare costs by 2050, they say.
'This scenario would increase global GDP by $269bn over the business-as-usual scenario. The health benefits from this intervention would be worth half a billion dollars if disability-adjusted life years are valued at the GDP per capita of a given country,' scientists noted.
In comparison, the worst-case scenario of an accelerated rise in AMR at the rate of the bottom 15 per cent of countries could lead to an additional 6.7 million people dying from infections, they warn.
The report comes following the UK government's Thursday announcement that it was axing the Fleming Fund – a major £265m British programme combating AMR in developing countries.
'Without effective interventions, health care costs could increase by $176bn per year by 2050, and global output could be $1.7trillion lower than in the business-as-usual scenario,' the report noted.
Previous research suggests that combating superbugs would require 6 to 15 new drugs developed for treatment per decade.
Scientists estimate this could require an annual additional research and development cost of $2.2bn.
'If all high-income countries funded this research and development in proportion to their GDP, it would cost them 0.0036 per cent of GDP in 2025,' they wrote.
'For these new drugs to provide the promised health benefits, people across the world must have access to them. We estimate that it would cost $59bn to ensure that all countries have outcomes for bacterial infections that match the quality of treatment currently available in the 85th percentile of countries,' researchers noted.
Considering these economic and health benefits, scientists say there would be 'excellent value for money' offered by these global interventions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
29 minutes ago
- The Guardian
Wes Streeting ‘thought he had struck deal to halt strike by doctors'
Wes Streeting thought he had struck a deal with resident doctors to stop a five-day strike in England, only for the British Medical Association to then reject it, sources have claimed. The health secretary believed he had secured a verbal agreement with the co-chairs of the BMA's resident doctors committee for a deal that involved progress on tackling five non-pay issues. Whitehall sources say Ross Nieuwoudt and Melissa Ryan decided the agreement made during face-to-face talks last Tuesday was enough for the suspension of the strike, which started on Friday. The deal would have involved resident doctors – formerly junior doctors – getting access to hot meals when working overnight, having some exam fees paid, receiving funding for equipment such as stethoscopes and getting mess rooms and changes to the way their postgraduate training was organised. But when Nieuwoudt and Ryan relayed the potential deal to the full committee, they were told they could not approve it because it did not address the BMA's demand that resident doctors receive a 29% pay rise over the next few years. 'They were told by the committee that they could only talk about pay and none of this soft stuff matters. Wes was furious. They had come incredibly close to a deal,' a source said. Resident doctors in England receive basic pay of between £38,831 and £73,992, with extra payments worth up to 15% of their salaries for working at weekends. The failure to reach a deal underlines the gulf between the BMA and Streeting. He has refused to reopen negotiations over the 5.4% salary increase he has given resident doctors this year. But the union is adamant it will call off industrial action only if he agrees to talk money. The BMA denied that it was responsible for the failure to strike a deal and blamed Streeting. A spokesperson said: 'We cannot be clearer: it was the government that ended the talks. 'Resident doctors do not want to strike. However, we have been compelled to take action because Mr Streeting's ultimatum, which demanded we call off strikes in exchange for nothing more than further talks was simply not acceptable. 'We want to continue our negotiations with Mr Streeting and strongly urge him to get back around the table with a serious proposal, rather than a handful of platitudes.' NHS bosses warn the strikes could 'snowball' and even continue into next year. They fear that nurses, consultant doctors and other NHS staff might stage strikes too. Sir Jim Mackey, the chief executive of NHS England, told the Sunday Times: 'We know that continued disruption over the coming months could see a snowball effect for patients and for staff. 'We've seen that before and it has take a huge effort over the last year to build momentum back up on reducing waiting lists and times.' His deputy, David Probert, who is also chief executive of University College London hospitals trust, told the same paper: 'This could be a marathon. We could be doing this until Christmas or maybe beyond.' The BMA's 55,000 resident doctor members have a legal mandate to take strike action for six months, until 6 January. Kemi Badenoch has pledged to outlaw strikes by doctors, bringing them into line with the police and army, if she becomes prime minister. 'Doctors hold lives in their hands. No one should lose critical healthcare because of strikes but that's what's happening now', the opposition leader posted on X on Sunday. 'That's why a Conservative government led by me would ban doctors' strikes, just like we do the army and police.'
BBC News
29 minutes ago
- BBC News
Bridgwater £17.8m diagnostic centre to improve access to 'vital scans'
A hospital trust has moved a step forward in its plans to construct a £17.8m diagnostic centre to improve access to vital NHS Foundation Trust has been given approval by NHS England to construct the facility next to Bridgwater Community Hospital. It said it has now applied for planning permission, which if approved could see the facility open next centre will run a range of services including two CT scanners, two MRI scanners, four outpatient rooms and two echocardiography and ultrasound director David Craig said the centre is "expected to provide almost 25,000 additional scans every year". This will enable the centre to provide the Bridgwater population with routine and specialist cardiac and cancer scanning, alongside clinics. It follows the opening of a community diagnostic centre in Taunton in 2020, as well as the development of a diagnostic centre next to Yeovil Hospital, which is expected to open later this year."This development is fantastic news for people in Bridgwater and will improve access to vital healthcare scans, as well as help us to reduce our waiting times," Mr Craig said."The new centre supports one of the three shifts of the NHS 10 Year Plan, which involves transferring care from hospitals into local communities."Running across seven days a week, it will improve access for people in Bridgwater and the surrounding areas to specialist care, with the centre expected to provide almost 25,000 additional scans every year."
The Independent
an hour ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.
